Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. The company reported quarterly sales of $2.360 million which beat the analyst consensus estimate of $1.630 million by 44.79 percent. This is a 357.36 percent increase over sales of $516.000 thousand the same period last year.
Omega Therapeutics Q1 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate, Sales $2.360M Beat $1.630M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.